Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preexisting Fundus Findings in a Large Cohort of Young Cynomolgus Macaques (<i>Macaca fascicularis</i>) Bred for Ocular Research: Comparison to Humans.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

The human cytomegalovirus vMIA protein inhibits apoptosis and innate immune signaling in human Mueller cells.

Experimental eye research·2026
Same author

Unveiling hidden intermediate states in protein folding with AI-based conditional transition clustering.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Dynamics of Gene and Allelic Expression During Modern Hybrid Maize Breeding.

Plant biotechnology journal·2026
Same author

Small-Portion Replacement with MnO<sub><i>x</i></sub> Media Promotes Biofilm Development, Leading to Rapid Biological Maturation and Sustained Mn(II) Removal in Sand Filtration.

Environmental science & technology·2026
Same author

The Use of Free-Living Amoeba in Treating Bacterial Infections: Thermotolerant Dictyostelids Are Avirulent and Do Not Cause Keratitis in Mice.

Investigative ophthalmology & visual science·2026

Related Experiment Video

Updated: Jun 22, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Gene therapy targeting glaucoma: where are we?

Xuyang Liu1, Carol A Rasmussen, B'ann T Gabelt

  • 1Department of Ophthalmology and Ophthalmic Laboratories, West China Hospital, Sichuan University, Chengdu, P.R. China.

Survey of Ophthalmology
|June 23, 2009
PubMed
Summary

Gene therapy offers a promising long-lasting ocular treatment for glaucoma, minimizing side effects and improving patient compliance. Advances in gene delivery and molecular understanding are making this innovative therapy a closer reality.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Biotechnology

Background:

  • Glaucoma is a chronic disease requiring long-term management.
  • Current treatments face challenges with patient compliance and systemic side effects.
  • Gene therapy presents a potential solution for sustained local ocular treatment.

Purpose of the Study:

  • To explore the potential of gene therapy for glaucoma treatment.
  • To highlight the advantages of gene therapy in overcoming compliance and side effect issues.
  • To discuss the advancements enabling ocular gene therapy.

Main Methods:

  • Review of current gene therapy techniques for ocular applications.
  • Analysis of molecular pathogenesis of glaucoma for targeted delivery.
  • Examination of improvements in vector construction and delivery methods.
  • Evaluation of animal models for preclinical studies.

Main Results:

  • Gene therapy can achieve long-lasting local effects in the eye.
  • It minimizes systemic side effects compared to traditional therapies.
  • Improved gene delivery and vector technology enhance feasibility.
  • Enhanced understanding of glaucoma's molecular basis allows for specific targeting.

Conclusions:

  • Gene therapy is a highly attractive therapeutic strategy for glaucoma.
  • Ongoing advancements in the field are bringing ocular gene therapy closer to clinical reality.
  • This approach addresses key limitations of current glaucoma management.